Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 13/20 | 0.54 |
| ▸ | BCHE | P06276 | 12/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TTPA | P49638 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463821 | 1.00 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9656754 | 1.00 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9313643 | 1.00 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL20764447 | 0.90 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4317784 | 0.88 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15820196 | 0.88 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9688177 | 0.88 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8542430 | 0.87 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9312815 | 0.87 | PTGS1 (0.58) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15820661 | 0.85 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128523-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2021-05-06 | — | — | US | claimed |
| US-20200206235-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2020-07-02 | — | — | US | claimed |
| EP-3672593-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| EP-3672592-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038360-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| WO-2019038361-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| US-5315017-A | Peroxidation and eicosanoid biosynthesis inhibition | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | claimed |
| EP-0487510-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | claimed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | claimed |
| US-12156862-B2 | Medicaments for the treatment of vasoconstriction related diseases or disorders | SULFATEQ B.V. (NL) | 2024-12-03 | — | — | US | disclosed |
| US-12156862-B2 | Medicaments for the treatment of vasoconstriction related diseases or disorders | SULFATEQ B.V. (NL) | 2024-12-03 | — | — | US | disclosed |
| US-11730741-B2 | 6-chromanol derivatives for use as a medicament | SULFATEQ B.V. (NL) | 2023-08-22 | — | — | US | disclosed |
| US-11730741-B2 | 6-chromanol derivatives for use as a medicament | SULFATEQ B.V. (NL) | 2023-08-22 | — | — | US | disclosed |
| WO-2019038361-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | disclosed |
| US-5395834-A | Antiarthritic agents or cardiovascular disorders | ADIR ET COMPAGNIE (FR) | 1995-03-07 | — | — | US | disclosed |
| US-5393775-A | Administering a (2-chromanyl)alkylcarboxylic acid for disorders connected with peroxidation processes | ADIR ET COMPAGNIE (FR) | 1995-02-28 | — | — | US | disclosed |
| US-5315017-A | Peroxidation and eicosanoid biosynthesis inhibition | ADIR ET COMPAGNIE (FR) | 1994-05-24 | — | — | US | disclosed |
| EP-0512899-A1 | Benzopyran compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-11-11 | — | — | EP | disclosed |